Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. — Stella
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(4 sites) United States
NEXT Oncology Dallas, Dallas, Texas Next Oncology, San Antonio, San Antonio, Texas Canada
Princess Margareth Cancer Center, Toronto, Ontario United Kingdom
Oxford University Hospital, Headington, Oxford
Key details Phase
Early testing / Safety & dosing
Sponsor
Auricula Biosciences Inc.
Collaborators
Simbec-Orion Group
Enrollment target
~110 participants
Primary completion
January 2028
Last updated January 2026